In cancers where Cav1 is downregulated, restoring its expression could increase sensitivity to chemotherapy and radiation therapy, inhibit pro-survival pathways (e.g., PI3K/AKT), and improve the efficacy of targeted therapies like EGFR inhibitors. The gene discussed is AKT1; the disease is cancer.